"Topotecan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
| Descriptor ID |
D019772
|
| MeSH Number(s) |
D03.132.151.850
|
| Concept/Terms |
Topotecan- Topotecan
- 9-Dimethylaminomethyl-10-hydroxycamptothecin
- 9 Dimethylaminomethyl 10 hydroxycamptothecin
Topotecan Hydrochloride- Topotecan Hydrochloride
- Hydrochloride, Topotecan
- Nogitecan Hydrochloride
- Hydrochloride, Nogitecan
- Topotecan Monohydrochloride, (S)-Isomer
SK&F-104864-A- SK&F-104864-A
- SK&F 104864 A
- SK&F104864A
- SKF-104864-A
- SKF 104864 A
- SKF104864A
|
Below are MeSH descriptors whose meaning is more general than "Topotecan".
Below are MeSH descriptors whose meaning is more specific than "Topotecan".
This graph shows the total number of publications written about "Topotecan" by people in this website by year, and whether "Topotecan" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Topotecan" by people in Profiles.
-
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study. Adv Ther. 2021 01; 38(1):350-365.
-
Status epilepticus associated with platinum chemotherapy in a patient with cervical cancer: a case report. BMC Cancer. 2015 Oct 17; 15:728.
-
Role of topotecan, vinorelbine, thiotepa and gemcitabine chemotherapy in relapsed/refractory adult acute leukemia. Leuk Lymphoma. 2015; 56(10):2962-4.
-
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? Int J Gynecol Cancer. 2013 Jun; 23(5):833-8.
-
A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). Gynecol Oncol. 2011 Mar; 120(3):454-8.
-
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther. 2009 Jul; 8(7):1867-77.
-
Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2004 Aug; 94(2):533-9.
-
Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors. Pediatr Blood Cancer. 2004 Jan; 42(1):93-8.
-
Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. Am J Med. 2004 Jan 01; 116(1):28-34.
-
Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies. Gynecol Oncol. 2003 Aug; 90(2):325-30.